Biomedcode participates at INFRAFRONTIER2020 Kick-Off meeting, April 24-25th in MunichINFRAFRONTIER aims to build a world-class research infrastructure that provides the biomedical research community with the tools needed to...
10 APR 2017
Select the type of mice you are interested in.
Therapeutic Areas - Animal models
21 JUL 2017
JANSSEN announces U.S. FDA approval of TREMFYA™ (GUSELKUMAB), the first approved biologic that selectively blocks interleukin (IL)-23, for the treatment of moderate-to-severe plaque psoriasisTREMFYA™ is the first and only biologic approved that selectively blocks interleukin (IL)-23. Seven out of ten patients receiving...
FAQ - Top 10 Questions
As with everything the best thing is to book your study in advance. The earlier you contact us, the easier will be to choose the exact date for the...
Client Testimonials - What our clients say about us
Quote from a Biopharmaceutical company, China
BioMedCode provided us with professional pharmacology study and high quality study reports, by using their novel and sophisticated transgenic mouse...
Events and Webinars
Biomedcode was founded in 2006, as a spin-off of the Biomedical Sciences Research Center “Alexander Fleming”
Biomedcode has extensive expertise & scientific excellence in inflammatory & autoimmune animal disease models
Our mouse models of arthritis were instrumental in proving the efficacy of anti-hTNF therapeutics in arthritis
Biomedcode’s clients include top 5 worldwide pharmaceutical companies
Targeted metabolic profiling of the Tg197 mouse model reveals itaconic acid as a marker of Rheumatoid Arthritis.Biomedcode coauthors a publication on the identification of a biomarker with translational value for the diagnosis & monitoring of rheumatoid...
Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept...Biomedcode's human TNF transgenic arthritis model, (Tg197), contributes to the non-clinical assessment of etanercept biosimilar GP2015 with...
Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis.Biomedcode's mouse models offered the in vivo non-clinical proof validating the efficacy of a novel composite hydrogel tacrolimus formulation for...